Eraxis is a brand name of anidulafungin, approved by the FDA in the following formulation(s):
ERAXIS (anidulafungin - injectable; iv (infusion))
Manufacturer: VICURON
Approval date: February 17, 2006
Strength(s): 50MG/VIAL [RLD]
Manufacturer: VICURON
Approval date: November 14, 2006
Strength(s): 100MG/VIAL [RLD]
Has a generic version of Eraxis been approved?
No. There is currently no therapeutically equivalent version of Eraxis available.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Eraxis. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Related Patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Cyclic peptide antifungal agents
Patent 5,965,525
Issued: October 12, 1999
Inventor(s): Burkhardt; Frederick J. & Debono; Manuel & Nissen; Jeffrey S. & Turner, Jr.; William W.
Assignee(s): Eli Lilly and Company
Provided are compounds of the formula (1): ##STR1## wherein R' is hydrogen, methyl or NH.sub.2 C(O)CH.sub.2 --; R" and R'" are independently methyl or hydrogen; R and R.sup.y are independently hydroxy or hydrogen; R.sub.1 is hydroxy, hydrogen, or hydroxysulfonyloxy; R.sub.7 is hydroxy, hydrogen, hydroxysulfonyloxy or phosphonooxy; R.sub.2 is a novel acyl side chain. Also provided are novel formulations, methods of inhibiting fungal and parasitic activity, and a process for preparing dideoxy (R=H) forms of the compounds.Patent expiration dates:
- February 17, 2020✓✓✓
- February 17, 2020
Cyclic peptide antifungal agents and process for preparation thereof
Patent 6,384,013
Issued: May 7, 2002
Inventor(s): Frederick J.; Burkhardt & Manuel; Debono & Jeffrey S.; Nissen & William W.; Turner, Jr.
Assignee(s): Eli Lilly and Company
Provided are compounds of the formula (1): wherein R′ is hydrogen, methyl or NH2C(O)CH2—; R″ and R′″ are independently methyl or hydrogen; R and Ry are independently hydroxy or hydrogen; R1 is hydroxy, hydrogen, or hydroxysulfonyloxy; R7 is hydroxy, hydrogen, hydroxysulfonyloxy or phosphonooxy; R2 is a acyl side chain. Also provided are formulations, methods of inhibiting fungal and parasitic activity, and a process for preparing dideoxy (R═H) forms of the compounds.Patent expiration dates:
- March 19, 2012✓
- March 19, 2012
Cyclic peptide antifungal agents and process for preparation thereof
Patent 6,743,777
Issued: June 1, 2004
Inventor(s): Frederick J.; Burkhardt & Manuel; Debono & Jeffrey S.; Nissen & William W.; Turner, Jr.
Assignee(s): Eli Lilly and Company
Provided are compounds of the formula (1): wherein R′ is hydrogen, methyl or NH2C(O)CH2—; R″ and R′″ are independently methyl or hydrogen; R adn Ry are independently hydroxy or hydrogen; R1 is hydroxy, hydrogen, or hydroxysulfonyloxy; R7 is hydroxy, hydrogen, hydroxysulfonyloxy or phosphonooxy; R2 is a novel acyl side chain. Also provided are novel formulations, methods of inhibiting fungal and parasitic activity, and a process for preparing dideoxy (R=H) forms of the compounds.Patent expiration dates:
- March 19, 2012✓✓
- March 19, 2012
Echinocandin pharmaceutical formulations containing micelle-forming surfactants
Patent 6,960,564
Issued: November 1, 2005
Inventor(s): Milton; Nathaniel & Moder; Kenneth Philip & Sabatowski; James Lawrence & Sweetana; Stephanie Ann
Assignee(s): Eli Lilly and Company
Pharmaceutical formulations are described comprising an echinocandin compound or echinocandin/carbohydrate complex and a pharmaceutically acceptable micelle-forming surfactant in a non-toxic aqueous solvent such that the solubilization of the echinocandin compound is optimized and the ability to freeze-dry the solution is maintained. Both the solution and freeze-dried formulations have increased stability. A bulking agent, tonicity agent buffer and/or a stabilizing agent may optionally be added to the formulations to further enhance the stability of the formulation.Patent expiration dates:
- April 12, 2021✓✓
- April 12, 2021
Echinocandin pharmaceutical formulations containing micelle-forming surfactants
Patent 7,709,444
Issued: May 4, 2010
Inventor(s): Milton; Nathaniel & Moder; Kenneth Philip & Sabatowski; James Lawrence & Sweetana; Stephanie Ann
Assignee(s): Pfizer Inc.
Pharmaceutical formulations are described comprising an echinocandin compound or echinocandin/carbohydrate complex and a pharmaceutically acceptable micelle-forming surfactant in a non-toxic aqueous solvent such that the solubilization of the echinocandin compound is optimized and the ability to freeze-dry the solution is maintained. Both the solution and freeze-dried formulations have increased stability. A bulking agent, tonicity agent buffer and/or a stabilizing agent may optionally be added to the formulations to further enhance the stability of the formulation.Patent expiration dates:
- April 12, 2021✓✓
- April 12, 2021
Related Exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
- Exclusivity expiration dates:
- February 17, 2011 - NEW CHEMICAL ENTITY
See also...
- Eraxis Consumer Information (Drugs.com)
- Eraxis Consumer Information (Wolters Kluwer)
- Eraxis Consumer Information (Cerner Multum)
- Eraxis Advanced Consumer Information (Micromedex)
- Eraxis AHFS DI Monographs (ASHP)
- Anidulafungin Consumer Information (Wolters Kluwer)
- Anidulafungin Consumer Information (Cerner Multum)
- Anidulafungin Intravenous Advanced Consumer Information (Micromedex)
- Anidulafungin AHFS DI Monographs (ASHP)
No comments:
Post a Comment